• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease
This study presents the results of over 10-year (median 133 months, range 95–149) safety follow-up of VIF-CAD patients. Overall, 12 (36.4%) patients died in VIF and 8 (42.1%) in Placebo group (P = .68). Cardiovascular mortality was 12/33 (36.4%) in the VIF group and 6/19 (31.6%) in Placebo group (P = .73). Two Placebo patients died due to malignancies, but no VIF patients (P = .17). The Kaplan–Meier curves of combined endpoint: cardiovascular mortality, myocardial infarction and stroke were similar for both patient groups (P = .71). Odds ratio of Placebo group increasing (re...
Source: American Heart Journal - June 20, 2019 Category: Cardiology Source Type: research

The Year in Review of Clinical Cardiac Electrophysiology
This past year saw multiple important advances in the field clinical cardiac electrophysiology. Seminal articles describing new anticoagulant drugs for stroke prevention in atrial fibrillation were published. New results that raise questions regarding the safety of dronedarone and several new promising techniques in AF ablation were described. Important articles that refine our understanding of the risk of sudden death among Wolff-Parkinson-White patients were published. In the basic and translational sciences, the application of gene therapy to the study and potential treatment of arrhythmias was described, whereas geneti...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - February 11, 2013 Category: Cardiology Source Type: research

Lipid-Lowering Agents
The role of lipid lowering in reducing the risk of mortality and morbidity from cardiovascular disease (CVD) is well established. Treatment particularly aimed at decreasing low-density lipoprotein cholesterol (LDL-C) is effective in reducing the risk of death from coronary heart disease and stroke. Statins form the cornerstone of treatment. However, in some individuals with a high risk of CVD who are unable to achieve their target LDL-C due to either intolerance or lack of efficacy, there is the need for alternative therapies. This review provides an overview of the different classes of currently available lipid-lowering m...
Source: Journal of Cardiovascular Pharmacology and Therapeutics - August 12, 2013 Category: Cardiology Authors: Ewang-Emukowhate, M., Wierzbicki, A. S. Tags: Cardiovascular Pharmacology Core Review Source Type: research

AAV-Mediated Gene Therapy for Atherosclerosis
Abstract The prognosis of patients with coronary artery disease and stroke has improved substantially over the last decade as a result of advances in primary and secondary preventive care as well as novel interventional approaches, including the development of drug-eluting stents and balloons. Despite this progress, however, cardiovascular disease remains the leading cause of death in industrialized nations. Sustained efforts to elucidate the underlying mechanisms of atherogenesis, reperfusion-induced cardiac injury, and ischemic heart failure have led to the identification of several target genes as key players ...
Source: Current Atherosclerosis Reports - August 3, 2014 Category: Cardiology Source Type: research

The Use of Gene Therapy for Ablation of Atrial Fibrillation
In the United States, atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting approximately six million patients and contributing to a greatly increased risk of stroke, heart failure (HF) and overall morbidity and mortality.1,2 The prevalence of AF is increasing as the average age of the population increases.3,4
Source: Radcliffe Cardiology - November 25, 2014 Category: Cardiology Authors: lravichander Source Type: research

Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial
Conclusions The blinded placebo-controlled STOP-HF trial demonstrated the safety of a single endocardial administration of pSDF-1 but failed to demonstrate its primary endpoint of improved composite score at 4 months after treatment. Through a pre-specified analysis the STOP-HF trial demonstrates the potential for attenuating LV remodelling and improving EF in high-risk ischaemic cardiomyopathy. The safety profile supports repeat dosing with pSDF-1 and the degree of left ventricular remodelling suggests the potential for improved outcomes in larger future trials.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Chung, E. S., Miller, L., Patel, A. N., Anderson, R. D., Mendelsohn, F. O., Traverse, J., Silver, K. H., Shin, J., Ewald, G., Farr, M. J., Anwaruddin, S., Plat, F., Fisher, S. J., AuWerter, A. T., Pastore, J. M., Aras, R., Penn, M. S. Tags: Heart failure/cardiomyopathy Source Type: research

Therapeutic Prospects of Gene Therapy for Atrial Fibrillation
Atrial Fibrillation (AF) is one of the most common types of cardiac arrhythmias experienced in clinical practice, increasing the risk of stroke, dementia, myocardial infarction and death. Currently available options for the treatment of AF use either pharmacological agents or catheter-based ablation therapies to restore sinus rhythm or control the ventricular response rate. These current treatment options are suboptimal at best, motivating research into discovering more effective and innovative ways to treat AF.
Source: Heart, Lung and Circulation - May 11, 2016 Category: Cardiology Authors: Melad Farraha, James J.H. Chong, Eddy Kizana Source Type: research

Attenuation of Oxidative Injury with Targeted Expression of NOX2 shRNA Prevents Onset and Maintenance of Electrical Remodeling in the Canine Atrium: A Novel Gene Therapy Approach to Atrial Fibrillation.
Conclusions: NOX2 oxidative injury: a) underlies onset as well as maintenance of electrical remodeling in AF, and b) can be successfully prevented with a novel, gene-based approach. Future optimization of this approach may lead to a novel, mechanism-guided therapy for AF. PMID: 32686471 [PubMed - as supplied by publisher]
Source: Circulation - July 19, 2020 Category: Cardiology Authors: Yoo S, Pfenniger A, Hoffman J, Zhang W, Ng J, Burrell A, Johnson DA, Gussak G, Waugh T, Bull S, Benefield B, Knight BP, Passman R, Wasserstrom JA, Aistrup GL, Arora R Tags: Circulation Source Type: research

Recent Advances in Gene Therapy for Atrial Fibrillation
This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - May 30, 2021 Category: Cardiology Authors: Shin Yoo, Gail Elizabeth Geist, Anna Pfenniger, Markus Rottmann, Rishi Arora Tags: REVIEW Source Type: research

New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease
Circ Res. 2021 Jun 11;128(12):1944-1957. doi: 10.1161/CIRCRESAHA.121.318266. Epub 2021 Jun 10.ABSTRACTThe prevalence of peripheral arterial disease (PAD) in the United States exceeds 10 million people, and PAD is a significant cause of morbidity and mortality across the globe. PAD is typically caused by atherosclerotic obstructions in the large arteries to the leg(s). The most common clinical consequences of PAD include pain on walking (claudication), impaired functional capacity, pain at rest, and loss of tissue integrity in the distal limbs that may lead to lower extremity amputation. Patients with PAD also have higher t...
Source: Circulation Research - June 10, 2021 Category: Cardiology Authors: Brian H Annex John P Cooke Source Type: research

Po-626-03 preclinical safety of adkcnh2-g628s for post-op af
Post-operative atrial fibrillation (POAF) occurs in 30% of cardiac surgeries, increasing risk of stroke, MI, and death. We propose gene therapy with an adenovirus encoding the G628S mutation of KCNH2 (AdKCNH2-G628S) to prevent POAF. We have reported preclinical efficacy in pigs.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: J. Kevin Donahue, David D. McManus Source Type: research

Lipid Lowering Therapy: An Era Beyond Statins
Curr Probl Cardiol. 2022 Jul 30:101342. doi: 10.1016/j.cpcardiol.2022.101342. Online ahead of print.ABSTRACTDyslipidemia, specifically elevated LDL cholesterol levels, causes atherosclerotic cardiovascular disease (ASCVD) and increases the risk of myocardial infarction and stroke. Statins, a class of drugs that exert their effects by inhibiting HMG-CoA reductase, a key enzyme in the synthesis of cholesterol, have been the mainstay of therapy for the primary prevention of cardiovascular disease and lipids reduction. Statins are associated with side effects, most commonly myopathy and myalgias, despite their proven efficacy....
Source: Atherosclerosis - August 2, 2022 Category: Cardiology Authors: Toufik Abdul-Rahman Syed Muhammad Awais Bukhari Emiliano Cantu Herrera Wireko Andrew Awuah Jannel Lawrence Heloisa de Andrade Neal Patel Rohan Shah Raheel Shaikh Camilo Andr és Avendaño Capriles Sebahat Ulusan Shahzaib Ahmad Anna Corriero Adriana C Mare Source Type: research

Bs-452758-4 combined gene therapy approach targets parasympathetic signaling and oxidative stress to attenuate persistent atrial fibrillation development in a canine model
Atrial fibrillation (AF) is the most common arrhythmia, a major risk factor for stroke and is associated with substantial morbidity and mortality. Unfortunately, current pharmacological and interventional treatment approaches are suboptimal. Parasympathetic nervous system (PNS) activity upregulation and oxidative stress (OS), mainly generated by NADPH oxidase 2 (NOX2), have been shown as key players in AF induction and maintenance. A deeper understanding of these molecular mechanisms underlying AF and their interplay will be instrumental to the development of new, mechanism-targeted therapies for AF.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Aleksei Mikhailov, Azaria Panni, Anna Pfenniger, Shin Yoo, David Johnson, Wenwei Zhang, Markus Rottmann, William Marszalec, Asish Ghosh, Rod S. Passman, Bradley P. Knight, Rishi Arora Source Type: research

Sestrin2 as a Potential Target in Hypertension
Diagnostics (Basel). 2023 Jul 14;13(14):2374. doi: 10.3390/diagnostics13142374.ABSTRACTHypertension is a highly complex, intricate condition affecting millions of individuals across the globe. Nearly half of adults in the United States are diagnosed with hypertension, with incident rates projected to rise over the next decade. Hypertension is a precursor to many cardiovascular diseases including atherosclerosis, stroke, myocardial infarction, heart failure, and peripheral artery disease. This review describes the major processes contributing to the development of hypertension and how Sestrin2 (Sesn2), an antioxidative prot...
Source: Atherosclerosis - July 29, 2023 Category: Cardiology Authors: Steven Didik Hao Wang Adewale Segun James Lily Slotabec Ji Li Source Type: research